RU2622021C2 - Лечение кахексии - Google Patents

Лечение кахексии Download PDF

Info

Publication number
RU2622021C2
RU2622021C2 RU2014111662A RU2014111662A RU2622021C2 RU 2622021 C2 RU2622021 C2 RU 2622021C2 RU 2014111662 A RU2014111662 A RU 2014111662A RU 2014111662 A RU2014111662 A RU 2014111662A RU 2622021 C2 RU2622021 C2 RU 2622021C2
Authority
RU
Russia
Prior art keywords
subject
patients
cachexia
mab
human
Prior art date
Application number
RU2014111662A
Other languages
English (en)
Russian (ru)
Other versions
RU2014111662A (ru
Inventor
Джон СИМАРД
Original Assignee
ИксБиотеч, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ИксБиотеч, Инк. filed Critical ИксБиотеч, Инк.
Publication of RU2014111662A publication Critical patent/RU2014111662A/ru
Application granted granted Critical
Publication of RU2622021C2 publication Critical patent/RU2622021C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2014111662A 2011-09-23 2012-09-21 Лечение кахексии RU2622021C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161538309P 2011-09-23 2011-09-23
US61/538,309 2011-09-23
PCT/US2012/056492 WO2013043973A2 (en) 2011-09-23 2012-09-21 Cachexia treatment

Publications (2)

Publication Number Publication Date
RU2014111662A RU2014111662A (ru) 2015-10-27
RU2622021C2 true RU2622021C2 (ru) 2017-06-08

Family

ID=47911521

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014111662A RU2622021C2 (ru) 2011-09-23 2012-09-21 Лечение кахексии

Country Status (16)

Country Link
US (2) US9809649B2 (OSRAM)
EP (1) EP2750709B1 (OSRAM)
JP (1) JP6204915B2 (OSRAM)
KR (1) KR102039198B1 (OSRAM)
CN (2) CN108404127B (OSRAM)
AU (1) AU2012312225B2 (OSRAM)
CA (1) CA2849710C (OSRAM)
DK (1) DK2750709T3 (OSRAM)
ES (1) ES2695102T3 (OSRAM)
IL (1) IL231622B (OSRAM)
MX (1) MX356808B (OSRAM)
PH (1) PH12014500645A1 (OSRAM)
PT (1) PT2750709T (OSRAM)
RU (1) RU2622021C2 (OSRAM)
WO (1) WO2013043973A2 (OSRAM)
ZA (1) ZA201402057B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2843348C2 (ru) * 2021-06-30 2025-07-14 ШАНХАЙ ДжейЭмТи-БАЙО ТЕКНОЛОДЖИ КО., ЛТД. Антитело к GFRAL и его применение

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159976A2 (en) 2010-06-18 2011-12-22 Xbiotech, Inc. Arthritis treatment
CN103153340A (zh) 2010-08-23 2013-06-12 埃克斯生物科技公司 对肿瘤疾病的治疗
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
ES2695102T3 (es) 2011-09-23 2019-01-02 Xbiotech Inc Tratamiento para la caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
US10485502B2 (en) * 2016-12-20 2019-11-26 General Electric Company System and method for assessing muscle function of a patient
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
CN110382001A (zh) 2017-02-16 2019-10-25 埃克斯生物科技公司 化脓性汗腺炎的治疗
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007135546A2 (en) * 2006-05-22 2007-11-29 Xbiotech Inc. TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES
WO2009148575A1 (en) * 2008-05-30 2009-12-10 Xbiotech, Inc. Interleukin-1 alpha abs and methods of use
US20100221179A1 (en) * 2009-01-29 2010-09-02 Abbott Laboratories IL-1 Binding Proteins

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5034316A (en) 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04504253A (ja) 1989-03-27 1992-07-30 セントカー・インコーポレーテツド ＩｇＭ抗体の安定化のための配合物
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1994008624A2 (en) 1992-10-14 1994-04-28 Sterling Winthrop Inc. Therapeutic and diagnostic imaging compositions and methods
ATE204299T1 (de) 1993-03-05 2001-09-15 Bayer Ag Humane monoklonale anti-tnf alpha antikörper
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5959085A (en) 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US20020131954A1 (en) 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
AU2007202323C1 (en) 2000-06-29 2012-04-12 Abbvie Inc. Dual specificity antibodies and methods of making and using
US20040086507A1 (en) 2000-10-19 2004-05-06 Kenya Shitara Antibody inhibiting vplf activity
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
AU2002343609B2 (en) 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
NZ566539A (en) 2002-09-06 2010-01-29 Medarex Inc Therapeutic human anti-IL-1R1 monoclonal antibody
JP4450644B2 (ja) 2003-03-03 2010-04-14 日本化薬株式会社 Ａｍｆ類を有効成分とする医薬製剤
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US8957056B2 (en) 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
US20050276807A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
WO2006036936A2 (en) 2004-09-27 2006-04-06 Bridge Pharma, Inc. The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
AU2005314392B2 (en) 2004-12-09 2011-04-14 Centocor, Inc. Anti-integrin immunoconjugates, methods and uses
DE602006014691D1 (de) 2005-08-02 2010-07-15 Xbiotech Inc DIAGNOSE, BEHANDLUNG UND PRÄVENTION VON GEFÄSSERKRANKUNGEN MITTELS IL-1alpha-AUTOANTIKÖRPERN
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1931383A1 (en) 2005-09-28 2008-06-18 Cytos Biotechnology AG Interleukin-1 conjugates and uses thereof
EP2021026A1 (en) 2006-04-14 2009-02-11 Novartis AG Use of il-i antibodies for treating ophthalmic disorders
ES2384278T3 (es) 2006-05-15 2012-07-03 Xbiotech, Inc IL-1-alfa para su uso en un procedimiento de tratamiento de placas ateroscleróticas
US20110008282A1 (en) 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
HRP20140172T1 (hr) 2006-05-30 2014-03-28 Genentech, Inc. Protutijela i imunokonjugati kao i njihove uporabe
EP2114443A4 (en) 2006-12-29 2011-08-10 Abbott Lab IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY
CN102056485A (zh) 2008-04-15 2011-05-11 萨可德公司 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂
AU2009291536B2 (en) 2008-09-12 2012-08-16 Xbiotech Inc. Targeting pathogenic monocytes
AR078650A1 (es) 2009-10-15 2011-11-23 Abbott Lab Anticuerpo de union a il-1 beta
WO2011159976A2 (en) 2010-06-18 2011-12-22 Xbiotech, Inc. Arthritis treatment
CN103153340A (zh) 2010-08-23 2013-06-12 埃克斯生物科技公司 对肿瘤疾病的治疗
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
DK2694107T3 (en) 2011-04-01 2018-12-10 Xbiotech Inc TREATMENT OF DERMATOLOGICAL DISORDERS
ES2695102T3 (es) 2011-09-23 2019-01-02 Xbiotech Inc Tratamiento para la caquexia
US20130195877A1 (en) 2012-01-31 2013-08-01 Xbiotech, Inc. Treatment of cachexia by targeting interleukin-1 beta
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
AU2013327501B2 (en) 2012-10-04 2018-08-09 Xbiotech Inc. Treating vascular disease and complications thereof
KR20150064091A (ko) 2012-10-04 2015-06-10 엑스바이오테크, 인크. 정신의학적 병태의 치료법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007135546A2 (en) * 2006-05-22 2007-11-29 Xbiotech Inc. TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES
WO2009148575A1 (en) * 2008-05-30 2009-12-10 Xbiotech, Inc. Interleukin-1 alpha abs and methods of use
US20100221179A1 (en) * 2009-01-29 2010-09-02 Abbott Laboratories IL-1 Binding Proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUMAR S. Et al. Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer // Am J Pathol. 2003 Dec;163(6):2531-41, фиг.2, фиг.3. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2843348C2 (ru) * 2021-06-30 2025-07-14 ШАНХАЙ ДжейЭмТи-БАЙО ТЕКНОЛОДЖИ КО., ЛТД. Антитело к GFRAL и его применение

Also Published As

Publication number Publication date
MX2014003402A (es) 2015-03-05
PT2750709T (pt) 2018-11-22
CN108404127A (zh) 2018-08-17
WO2013043973A2 (en) 2013-03-28
AU2012312225A1 (en) 2014-04-10
RU2014111662A (ru) 2015-10-27
KR102039198B1 (ko) 2019-10-31
JP2014526559A (ja) 2014-10-06
US20180037647A1 (en) 2018-02-08
PH12014500645A1 (en) 2014-05-05
AU2012312225B2 (en) 2017-10-05
ES2695102T3 (es) 2019-01-02
EP2750709A4 (en) 2015-06-10
US9809649B2 (en) 2017-11-07
IL231622A0 (en) 2014-05-28
HK1199616A1 (en) 2015-07-10
ZA201402057B (en) 2016-08-31
CA2849710C (en) 2020-04-28
US10202449B2 (en) 2019-02-12
EP2750709B1 (en) 2018-08-15
MX356808B (es) 2018-06-14
IL231622B (en) 2018-10-31
KR20140078690A (ko) 2014-06-25
CN108404127B (zh) 2025-12-12
US20130078258A1 (en) 2013-03-28
EP2750709A2 (en) 2014-07-09
DK2750709T3 (en) 2018-12-03
CN103906536A (zh) 2014-07-02
JP6204915B2 (ja) 2017-09-27
CA2849710A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
RU2622021C2 (ru) Лечение кахексии
US11932688B2 (en) Treatment for neoplastic diseases
KR20130098279A (ko) 관절염 치료
US20130195877A1 (en) Treatment of cachexia by targeting interleukin-1 beta
JP2022530063A (ja) 抗体製剤
HK1199616B (en) Cachexia treatment
HK1229696B (en) Treatment for neoplastic diseases

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
PC41 Official registration of the transfer of exclusive right

Effective date: 20210526

TK4A Correction to the publication in the bulletin (patent)

Free format text: CORRECTION TO CHAPTER -PC4A- IN JOURNAL 15-2021 FOR INID CODE(S) D N